August 8, 2024

SEATTLE, WA, August 1, 2004 (Globe Newswire) Outpace Bio, a cell therapy company using unrivaled AI-powered protein design to program immune cells for improved function inside patients battling solid tumors, today announced that it has raised $144 million in an oversubscribed Series B financing. FLG partner Greg Curhan, assisted.

Read the full press release.